Drug Trial Radar · NCT06230822
Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Mar 5, 2024
Primary completion
Mar 13, 2025
Study completion Aug 1, 2025
Sponsor
- Lead sponsor
- Wuhan Optics Valley Vcanbiopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-arm, multiple-dose, dose-escalation, open-label multicenter clinical trial, aiming to evaluate the safety, tolerability, and preliminary efficacy of VUM02 Injection for treatment of idiopathic pulmonary fibrosis (IPF). VUM02 Injection (Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection, hUCT-MSC) is an allogeneic cell therapy product comprising culture-expanded Mesenchymal Stem Cells derived from the human umbilical cord tissue. The product is cryopreserved with the amount of 5 x 10\^7 cells per 10 mL per bag (5 x 10\^6 cells/mL). This study is a multiple-dose tolerability study following the "3+3" dose escalation principle and progressing from the low-dose group to the high-dose group sequentially. Three to six patients will be enrolled in each dose group and administered every 3 days for a total of 3 doses.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
VUM02 InjectionDrug
VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of cell therapy-related adverse events (AEs) as assessed by CTCAE (V5.0)Time frame: 28 days
- Maximum tolerated dose (MTD)Time frame: 28 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, China
West China Hospital of Sichuan University
Chengdu, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
The First People's Hospital of Kashi Prefecture, Xinjiang
Kashgar, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.